Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders
NCT07371325Completed
- Start
- Sep 2024
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Randomised, double-blind trial in schizophrenia and metabolic syndrome (4 arms). Primary endpoint: Metabolic Disturbances at 12 weeks. Started Sep 2024; status: completed.
02
Conditions
schizophreniametabolic syndrome
Beyond the preview
Go deeper on NCT07371325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371325.